Long-Term Real-World Use of Cabotegravir/Rilpivirine: Adherence and Virological Efficacy over a 44-Month Observation Period.

ABSTRACT:

Introduction

Long-acting cabotegravir/rilpivirine (LA-CAB/RPV) offers an effective alternative to daily oral antiretroviral therapy (ART) for people living with human immunodeficiency virus (PLWH), especially those with adherence challenges. Despite increasing use of LA-CAB/RPV, long-term real-world data on durability, adherence, and virological outcomes remain limited to 2 years. This study provides detailed longitudinal data at the individual PLWH level, assessing adherence, safety, and efficacy over a period of up to 10 years.

Methods

All PLWH receiving LA-CAB/RPV at the University Medical Center Hamburg-Eppendorf between 2021 and 2025 were analyzed over 44 months, including injection-naïve individuals and former registration trial participants. Clinical, laboratory, immu

SUBMITTER: Dannenberg C 

PROVIDER: S-EPMC12339819 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature